News Medical on MSN10d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, ...
MedPage Today on MSN8d
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
Two ARIA-related deaths were attributed to donanemab in that study. ARIA occurred more frequently in APOE4 homozygotes than ...
Nature5d
Hyperdibasicaminoaciduria: An Inherited Disorder of Amino Acid Transport [34]
It allows one to discriminate the carriers of the trait, who presumably are heterozygotes, from carriers of the various cystinuric genotypes. The trait is expressed consistently with regard to ...
Eli Lilly announces MHRA grants marketing authorization for donanemab
Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...
Pulse14d
NICE rules newly-approved Alzheimer’s-slowing drug too costly for NHS
The UK medicines regulator has today approved a new treatment that can slow Alzheimer’s disease progression, but NICE has ...
Medscape2d
Update on the Pharmacogenomics of Proton Pump Inhibitors
Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles ...
Pharmabiz13d
UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease
UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...
eLife7d
Protein absorption in the zebrafish gut is regulated by interactions between lysosome rich enterocytes and the microbiome
Dietary protein absorption in neonatal mammals and fishes relies on the function of a specialized and conserved population of highly absorptive lysosome rich enterocytes (LREs). The gut microbiome has ...
Lifetime Achievement Award, Lecanemab And Biomarkers In Focus At CTAD
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...
Finanznachrichten12d
Biogen Inc.: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
4 Heterozygotes or Non-Carriers, Wednesday, October 30, 11:20 AM One-Year Experience on the Use of Lecanemab in Clinical Practice, Wednesday, October 30, 3:30 PM AI-Derived Prognostic Covariates ...